July 30: The Week in Cancer News
Healthy lifestyle habits can reduce the risk of cancer, and other cancer research news of the week selected by the staff of Cancer Today magazine.
Progress Against Cancer
Healthy lifestyle habits can reduce the risk of cancer, and other cancer research news of the week selected by the staff of Cancer Today magazine.
Exercise, healthful diet, no smoking or drinking are correlated with lower risk for cancer even in people with higher risk based on their genetic makeup.
The U.S. FDA approved the immune checkpoint inhibitor pembrolizumab combined with chemotherapy to treat certain breast cancer patients before surgery. The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic pembrolizumab for patients with...
Two studies on access to opioids identify disturbing patterns, and more news of the week from Cancer Today.
The U.S. FDA approved a combination of a molecularly targeted therapeutic and an immunotherapeutic to treat certain patients with uterine cancer. The U.S. Food and Drug Administration (FDA) approved the combination of the immunotherapeutic...
Recently published clinical trial results suggest that combining an investigational antibody therapy with chemotherapy may be an effective strategy for patients with relapsed disease.
A study measures the global impact of alcohol on cancer incidence, and more news of the week from Cancer Today.
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today Cancers that grow and disseminate to threaten life reside amid many types of noncancerous cells, including blood vessel cells, supportive cells called fibroblasts, and...
Study shows cancer centers can improve coordination with physicians’ practices in their networks, and more news of the week from Cancer Today.
The U.S. FDA approved a monoclonal antibody and enzyme combination for use in conjunction with chemotherapy and a steroid to treat patients with multiple myeloma. The U.S. Food and Drug Administration (FDA) approved...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More